Services > All services > Memory Center > Loma Linda University Medical Center East Campus - Memory Center - Research



Loma Linda University Health Care Department of Neurology is committed to research for memory disorders. Through ongoing studies and clinical trials, we are finding new solutions and prevention methods to slow the onset of memory loss.


Research Findings

Amyloid Deposits in Cognitively Normal People May Predict Risk for Alzheimer’s Disease

December 14, 2009 -- For people free of dementia, abnormal deposits of a protein associated with Alzheimer’s disease are associated with increased risk of developing the symptoms of the progressive brain disorder, according to two studies from researchers at Washington University in St. Louis.  

Recovery Funds Advance Alzheimer's Disease Research

November 23, 2009 -- American Recovery and Reinvestment Funds are being used to promote the national research efforts to better understand, diagnose and treat Alzheimer’s disease. The National Institute on Aging (NIA) has targeted promising areas of research in granting the awards, such as new and ongoing studies to identify additional risk factor genes associated with Alzheimer’s, improve diagnostic tools, find biomarkers, develop therapies, conduct clinical trials and explore preventive measures. 

Scientists Identify Two Gene Variants Associated with Alzheimer’s Risk

September 8, 2009 -- In the largest genome-wide association study (GWAS) reported to date involving Alzheimer’s disease, scientists have identified two new possible genetic risk factors for late-onset Alzheimer’s, the most common form of the disease. The study, which pooled DNA samples from a number of European and U.S. groups, not only associated variations in the sequence of the CLU and PICALM genes with increased risk, but also found another 13 gene variants that merit further investigation, according to findings presented in the September 6, 2009, online issue of Nature Genetics.   

Scientists Report Important Step in Biomarker Testing for Alzheimer’s Disease

March 17, 2009 -- Scientists have made a significant step forward in developing a test to help diagnose the early stages of Alzheimer’s disease sooner and more accurately by measuring two biomarkers—tau and beta-amyloid proteins—in cerebrospinal fluid. In a new report, researchers from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) not only confirmed that certain changes in biomarker levels in cerebrospinal fluid may signal the onset of mild Alzheimer’s, but also established a method and standard of testing for these biomarkers.